Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCSXNW)

• Drug Name: CACOSPONGIONOLIDE B Drug Info
• Synonyms: cacospongionolide B; CHEMBL111739

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10386285
  TTD Drug ID: DMCSXNW

Molecule-Related Drug Atlas

Drug(s) Targeting Group IIA phospholipase A2 (GIIA sPLA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KH064	DMR1NYF	Breast cancer	2C60-2C65	Clinical trial	[2]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[3]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[3]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[4]
2-(4-phenoxyphenoxy)ethanamine	DM7TBUJ	Discovery agent	N.A.	Investigative	[5]
CACOSPONGIONOLIDE	DMIPJUS	Discovery agent	N.A.	Investigative	[1]
Elaidoylamide	DMP8VDT	Discovery agent	N.A.	Investigative	[3]
Cacospongionolide E	DM2DYAV	Discovery agent	N.A.	Investigative	[1]
N-Tridecanoic Acid	DMNZ37C	Discovery agent	N.A.	Investigative	[4]
BOLINAQUINONE	DMVB6UG	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Phospholipase A2 (PLA2G1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[3]
Miltefosine	DMND304	Chronic urticaria		Approved	[7]
Clocortolone	DM9ZMQH	Exanthem		Approved	[8]
Clobetasol	DMUXP52	Rosacea	ED90.0	Approved	[9]
Diflorasone	DMI9PRJ	Exanthem		Approved	[10]
AllerB	DM78DOT	Allergy	4A80-4A85	Phase 2b	[11]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[12]
MANOALIDE	DMB4A8I	Arthritis	FA20	Phase 2	[13]
MRX-4	DMQZWYE	Allergic rhinitis	CA08.0	Phase 2	[14]
MRX-6	DMLVQKF	Contact dermatitis	EK0Z	Phase 2	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Group IIA phospholipase A2 (GIIA sPLA2)	TTO8QRU	PA2GA_HUMAN	Inhibitor	[1]
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Inhibitor	[1]

References

• [1] A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
• [2] D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
• [3] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [4] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [5] Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
• [6] New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
• [7] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [8] Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
• [9] Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
• [10] Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
• [11] Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
• [12] Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
• [13] Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
• [14] Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
• [15] A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.